Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R known ✓ | P07333 | 4/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.56 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.56 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.56 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.56 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.56 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.56 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.56 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.56 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.56 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29973836 | 1.00 | CSF1R (0.98) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1268018 | 0.99 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL29431664 | 0.99 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL28770362 | 0.89 | CSF1R (0.81) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1268059 | 0.88 | CSF1R (0.80) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267263 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267961 | 0.87 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1266888 | 0.87 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267706 | 0.87 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL12646996 | 0.87 | CSF1R (0.78) | CSF1RKITCYP2C19LCKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4427810-A2 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4393547-A2 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240151713-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3886875-B1 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240115612-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11944647-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3886894-B1 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3676403-A1 | GENE EXPRESSION AND ASSESSMENT OF RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY | Juno Therapeutics, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2020113194-A2 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113188-A2 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| CN-111201438-A | Articles and methods relating to toxicity associated with cell therapy | 朱诺治疗学股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| US-20200147136-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200110077-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20190292246-A1 | COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA IMHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3534940-A1 | COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA INHIBITOR | Juno Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2019046832-A1 | GENE EXPRESSION AND ASSESSMENT OF RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018093591-A1 | COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147136-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | CSF1R 105/4885KIT 264/4885LCK 130/4885 |
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | CSF1R 105/4885KIT 264/4885LCK 130/4885 |
| US-20240151713-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | TNF, IL2, PBK | CSF1R 46/4885KIT 13/4885LCK 1025/4885 |
| US-20190292246-A1 | COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA IMHIBITOR | NFATC1, GMFG, KEAP1 | CSF1R 46/4885KIT 198/4885LCK 1707/4885 |
| US-20200110077-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | TNF, IL2, PBK | CSF1R 46/4885KIT 13/4885LCK 1025/4885 |
| US-11944647-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | ICOS, PBK, BCL6 | CSF1R 105/4885KIT 264/4885LCK 130/4885 |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | CD4, CD2, ICOS | CSF1R 84/4885KIT 675/4885LCK 36/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | CSF1R 46/4885KIT 220/4885LCK 223/4885 |
| US-20240115612-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | CSF1R 105/4885KIT 264/4885LCK 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.